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Colon cancer is one of the most common malignancies in adults
worldwide (Parkin, 2001). About 17000 new cases are diagnosed
each year in England and Wales, where it is the second and third
most frequent cancer in women and men, respectively. Over the
last 25 years, incidence has risen slightly in men, but has remained
fairly stable in women (Quinn et al, 2001). Of the improvements in
survival reported in Europe during the 1990s, one of the largest
absolute increases was for large bowel cancer (colon and rectum
combined). Survival increased more slowly in the UK during this
period than in other western European countries (Sant et al, 2001).
Substantial deprivation gradients in colon cancer survival have
been reported, both in England and Wales (Coleman et al, 1999)
and in other countries (Auvinen, 1992; Monnet et al, 1993). These
have been attributed in part to differential access to chemotherapy
(Corazziari et al, 2004) or specialised treatment centres (Herbert
et al, 2002; Satagopan et al, 2004).
We analysed the data for 206879 adults diagnosed with colon
cancer in England and Wales during the period 1986–1999, some
83% of the 250445 eligible. About 12% of patients who were
otherwise eligible for analysis were excluded with zero recorded
survival (date of diagnosis same as date of death). Up to a third of
these may in fact have died on the day of diagnosis (Coleman et al,
1999), but most were registered solely from a death certificate, and
the two categories could not be distinguished in national data. For
these two groups of patients, survival was either actually zero or
shorter than average (Berrino et al, 1995), respectively, and their
exclusion leads to some inflation of the survival estimates. The
proportion of cases with zero recorded survival was similar in all
socioeconomic groups, however, and it declined steadily during
the 1990s, again similarly in all socioeconomic groups (data not
shown). Exclusions from analysis for zero survival are thus
unlikely to have had any substantial impact on socioeconomic
gradients in survival, or on trends in the gradient. A further 3.5%
of patients with colon cancer were excluded because it was not
their first primary cancer.
The proportion of colon tumours recorded as adenocarcinoma
rose from 60 to 72% by 1999, but the proportion of poorly
specified carcinomas fell from 31 to 14%, suggesting improvement
in the quality of pathology data, and that the true proportion of
adenocarcinomas was probably approximately 70% throughout the
1990s. A very similar pattern was seen in the pathology of rectal
cancers. Information on the clinical stage at diagnosis was not
generally available in the national cancer registry before 1995, and
stage-specific analyses for the period 1986–1999 were thus not
possible.
Annual incidence rates in both men and women rose by
about one-fifth overall during 1986–1999, but the increase
was notably smaller in the most deprived group, also in both
sexes (Figure 1).
SURVIVAL TRENDS
Relative survival up to 10 years after diagnosis has increased
substantially in both sexes (Figure 2). In men, 1-year survival rose
from 61.9% for those diagnosed in the late 1980s to 68.9% for those
diagnosed in the late 1990s. This represents a significant average
increase of 5.5% every 5 years, after adjustment for deprivation.
Five-year survival rose from 39.5 to 47.6% (þ5.6% every 5 years)
over the same period. The survival rates and trends over time for
women were closely similar to those for men (Table 1).
Short-term predictions of survival for patients diagnosed during
2000–2001, using hybrid analysis (Brenner and Rachet, 2004),
suggest that the rapidly increasing trends in survival up to 10 years
after diagnosis observed during the 1990s are likely to continue in
the near future (Table 1).
DEPRIVATION
Survival has been significantly lower for both men and women in
the most deprived socioeconomic groups of the population since
1986 (Figure 3). The deprivation gap in 1-year survival has been
similar for men and women, and it has widened steadily and
significantly in both sexes, reaching  7% for patients diagnosed
during 1996–1999 (Table 2). For 5-year survival, the survival
deficit for the poorest patients has been slightly but consistently
wider for women than men. It also widened steadily and
significantly from 1986 to 2001. Between 1986–1990 and 1996–
1999, the deprivation gap in 5-year survival increased from  2.2 to
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www.bjcancer.com 5.7% in men (fitted average change  1.9% every 5 years) and
from  3.3 to  7.3% in women ( 2.2% every 5 years).
Short-term predictions of survival by socioeconomic group, again
using hybrid analysis, do not suggest any imminent reduction in the
deprivation gap in survival up to 10 years (Table 2).
COMMENT
Substantial improvements in colon cancer survival have occurred
for patients who were diagnosed in England and Wales during the
14-year period 1986–1999 and followed up to the end of 2001. The
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Figure 1 Trends in the age-standardised incidence of colon cancer in
adults aged 15–99 years, by sex and deprivation group: England and Wales,
1986–1999.
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Figure 2 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival
estimated with cohort or complete approach (1986–1990, 1991–1995,
1996–1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 61.9 (61.3, 62.5) 65.6 (65.1, 66.2) 68.9 (68.4, 69.5) 5.5** (4.5, 6.6) 69.7 (68.9, 70.4)
Women 60.1 (59.6, 60.7) 62.9 (62.4, 63.4) 66.5 (65.9, 67.0) 4.4** (3.3, 5.4) 66.9 (66.1, 67.7)
5 years Men 39.5 (38.9, 40.2) 42.8 (42.2, 43.4) 47.6 (46.8, 48.3) 5.6** (4.2, 7.0) 48.6 (47.6, 49.5)
Women 39.7 (39.1, 40.3) 42.2 (41.7, 42.8) 47.4 (46.7, 48.1) 5.6** (4.3, 6.8) 48.2 (47.3, 49.1)
10 years Men 35.7 (35.0, 36.5) 39.0 (38.2, 39.8) 5.2** (2.5, 7.9) 44.9 (43.8, 46.0)
Women 36.8 (36.2, 37.5) 39.0 (38.4, 39.7) 5.3** (2.9, 7.7) 45.0 (44.0, 46.0)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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been more rapid than for those diagnosed in the 1970s or 1980s
(Coleman et al, 1999). These trends are coherent with the
continuing decline in mortality and the steady rise in incidence
over the same period (Quinn et al, 2001). The increase in survival
may be attributable to improvements in surgery (McArdle and
Hole, 2002) and to reduction in operative mortality (Mitry et al,
2002). Taken together, the trends suggest that national improve-
ments in colon cancer survival may be attributable both to earlier
diagnosis and to improved treatment.
It seems unlikely that the divergence in incidence trends
between the poorest fifth of the population and all four of the
more affluent groups could be attributable to earlier diagnosis,
with colonoscopy somehow being less accessible to the least
affluent fifth of society alone, in part because the divergence in
incidence has persisted for at least 10 years. Nor could such a
pattern plausibly explain the widening deprivation gap in survival,
as benign and in situ tumours were all excluded from analysis: only
first primary, invasive malignant tumours were included. Bias in
both the overall survival estimates and the socioeconomic gap in
survival could, in principle, arise from the exclusion of a
substantial minority of patients whose recorded survival was zero,
and for many of whom the actual duration of survival was
unknown. This cannot plausibly explain the increasing deprivation
gap in survival, however, as the proportion of patients with zero
recorded survival was closely similar in all deprivation groups,
throughout the 1990s.
Improvements in colon cancer survival in the 15 years up to
2001 were more marked among residents of wealthier districts,
both men and women. As a result, the deprivation gap in survival
between the most affluent and the most deprived groups increased
steadily. The relative survival estimates take account of the
divergent trends in overall mortality between socioeconomic
groups over the 15 years up to 2001. This suggests that more
affluent patients have benefited preferentially from progress in
early diagnostic procedures and in access to optimal treatment
over this period.
Other evidence also suggests that the deprivation gradient in
relative survival for patients diagnosed in England and Wales
during the 1990s is likely to be due to a combination of earlier
diagnosis and better treatment in more affluent groups. Colorectal
cancer patients living in more deprived areas who were diagnosed
in southeast England during 1992–1995 were more likely to be
admitted as an emergency and less likely to have surgery (Pollock
and Vickers, 1998). Adjustment for stage at diagnosis did not
abolish the deprivation gradient in survival seen in this region
(Schrijvers et al, 1995). Population-based colorectal cancer
survival also varies with socio-economic status in the United
States (Singh et al, 2004), but patients from different racial or
socioeconomic groups who receive the same treatment appear to
have similar outcomes, whether this is in equal access health
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Figure 3 Trends in the deprivation gap in 5-year relative survival
(%) by sex and calendar period of diagnosis: England and Wales,
adults (15–99 years) diagnosed during 1986–1999 and followed up to
2001.
Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  2.9** ( 4.5,  1.2)  5.1** ( 6.6,  3.6)  7.1** ( 8.7,  5.6)  2.2** ( 3.5,  1.0)  7.8** ( 10.0,  5.6)
Women  4.2** ( 5.7,  2.6)  5.3** ( 6.8,  3.9)  6.7** ( 8.3,  5.1)  1.4* ( 2.5,  0.2)  6.8** ( 9.1,  4.5)
5 years Men  2.2* ( 4.1,  0.3)  4.3** ( 6.1,  2.6)  5.7** ( 8.0,  3.4)  1.9* ( 3.4,  0.3)  6.0** ( 8.8,  3.3)
Women  3.3** ( 5.0,  1.6)  6.2** ( 7.8,  4.5)  7.3** ( 9.4,  5.1)  2.2** ( 3.6,  0.8)  7.2** ( 9.8,  4.5)
10 years Men  1.3 ( 3.5, 0.8)  4.0** ( 6.3,  1.8)  2.7 ( 5.8, 0.4)  5.3** ( 8.6,  2.1)
Women  3.1** ( 5.0,  1.3)  7.1** ( 9.1,  5.1)  4.0** ( 6.7,  1.3)  7.9** ( 10.9,  4.9)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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2003), or within clinical trials (Dignam et al, 1999). Data from
France (Mitry et al, 2005) suggest that adjuvant chemotherapy
after resection with curative intent could account for much of the
national improvement in colon cancer survival in England and
Wales during the 1990s, and the increasing deprivation gradient in
survival may therefore reflect better access to optimal treatment
for patients living in more affluent areas.
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